ReviewHepatology international2015
Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.
Review in Hepatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Hepatology international · 2016Guideline
- Review
- Hepatitis C Virus-Pediatric and Adult Perspectives in the Current Decade.Pathogens (Basel, Switzerland) · 2024Review
- Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview.Microorganisms · 2022Review
- Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.Internal medicine (Tokyo, Japan) · 2022Article
- Article
- Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir.Internal medicine (Tokyo, Japan) · 2021Article
- The changing epidemiology of liver diseases in the Asia-Pacific region.Nature reviews. Gastroenterology & hepatology · 2019Review
- Systematic overview of hepatitis C infection in the Middle East and North Africa.World journal of gastroenterology · 2018Article
- Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.Hepatology international · 2018Article
- Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin.Biology · 2017Article
- Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.PloS one · 2017Article
- Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.Hepatology international · 2016Observational
- Hepatitis C virus genotypes in Myanmar.World journal of gastroenterology · 2016Article
- Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.International journal of medical sciences · 2016Article
- Past, Present, and Future of Viral Hepatitis in Bangladesh.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-1.0, 14.7, 0.1-0.3, 0.9-1.9, 1.0-2.0, 5, 4.4-8.6 and 0.5-1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60-70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.